Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Background Alzheimer's disease is a progressive, irreversible, and fatal disease for which
accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is …

Importance The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that …

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …

Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with
mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab …

The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …

Background This review describes the research and development process of
gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat …

Reported prevalence estimates of sporadic cerebral amyloid angiopathy (CAA) vary widely.
CAA is associated with cognitive dysfunction and intracerebral hemorrhage, and linked to …

In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for
Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results …